Cencora (NYSE:COR) Given New $405.00 Price Target at Wells Fargo & Company

Cencora (NYSE:COR) had its price objective increased by analysts at Wells Fargo & Company from $354.00 to $405.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 11.41% from the stock’s previous close.

A number of other research analysts have also commented on COR. Mizuho boosted their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday. TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday. Finally, Morgan Stanley set a $330.00 price target on shares of Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $360.55.

Cencora Stock Performance

COR traded down $1.13 on Tuesday, hitting $363.52. The company’s stock had a trading volume of 40,794 shares, compared to its average volume of 1,535,220. The company’s 50 day simple moving average is $315.73 and its 200-day simple moving average is $300.12. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora has a 12 month low of $223.92 and a 12 month high of $366.03. The firm has a market cap of $70.48 billion, a P/E ratio of 37.32, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the company earned $3.34 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora will post 15.37 EPS for the current year.

Insider Activity

In related news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 41,544 shares of company stock valued at $12,230,941. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Several hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new position in shares of Cencora during the second quarter valued at approximately $695,215,000. Mizuho Markets Americas LLC boosted its holdings in Cencora by 116.4% in the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after acquiring an additional 1,511,906 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Cencora in the second quarter worth $411,888,000. Invesco Ltd. increased its holdings in shares of Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after acquiring an additional 1,364,433 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after purchasing an additional 1,125,661 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.